2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice | Le, Xiuning; Sakai, Hiroshi; Felip, Enriqueta; Veillon, Remi; Garassino, Marina Chiara; Raskin, Jo; Cortot, Alexis B; Viteri, Santiago; Mazieres, Julien; Smit, Egbert F; Thomas, Michael; Iams, Wade T; Cho, Byoung Chul; Kim, Hye Ryun; CHIH-HSIN YANG ; Chen, Yuh-Min; Patel, Jyoti D; Bestvina, Christine M; Park, Keunchil; Griesinger, Frank; Johnson, Melissa; Gottfried, Maya; Britschgi, Christian; Heymach, John; Sikoglu, Elif; Berghoff, Karin; Schumacher, Karl-Maria; Bruns, Rolf; Otto, Gordon; Paik, Paul K | Clinical cancer research : an official journal of the American Association for Cancer Research | 48 | 39 | |
2023 | Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial | Mazieres, Julien; Paik, Paul K; Garassino, Marina C; Le, Xiuning; Sakai, Hiroshi; Veillon, Remi; Smit, Egbert F; Cortot, Alexis B; Raskin, Jo; Viteri, Santiago; Wu, Yi-Long; CHIH-HSIN YANG ; Ahn, Myung-Ju; Ma, Rui; Zhao, Jun; O'Brate, Aurora; Berghoff, Karin; Bruns, Rolf; Otto, Gordon; Johne, Andreas; Felip, Enriqueta; Thomas, Michael | JAMA oncology | 12 | 4 | |